Misha D.P. Luyer

Featured in: Favicon

Articles

An update on the PERISCOPE II trial; A multicentre RCT comparing gastrectomy, CRS and HIPEC to systemic chemotherapy alone for gastric cancer patients with limited peritonitis carcinomatosis

Feb 21, 2023 | ejso.com | Marieke Vollebergh |Valesca P. Retèl |Misha D.P. Luyer |Bas PL Wijnhoven |Epidemiology HTA

Background: Prognosis of synchronous peritoneal metastasis (PM) in gastric cancer patients is very poor, with a median overall survival of 4 months. Palliative systemic chemotherapy is the standard treatment for gastric cancer patients with PM in the Netherlands. There are no potentially curative treatment options. PM, in contrast to lymphatic and haematogenous dissemination, should be regarded as locoregional extension of disease.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.